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Sir,
In a recent paper, Lehrer and co-authors report that levels of
serum insulin were significantly higher in men that the authors
defined as high risk prostate cancer patients in comparison to
patients with low or intermediate risk (Lehrer et al, 2002). Patients
were assigned to risk category according to an evaluation of local
tumour stage, tumour differentiation and serum level of prostate
specific antigen (PSA). In essence, low risk patients had small
tumours of high differentiation and low PSA, whereas high-risk
patients had large tumours of poor differentiation and high PSA.
The authors conclude that their data were suggestive of an
association between insulin levels and advanced prostate cancer
stage and that insulin may possibly be used as a biomarker of
advanced stage in prostate cancer. Stimulated by Lehrer et al.w e
reanalysed data from a previously published study in we found no
significant association between prostate cancer risk and insulin
levels in blood samples obtained median time 3.9 years before
diagnosis (Stattin et al, 2000). In contrast to what Lehrer and
colleagues observed in their study, we found only mild, non-
significant increases in insulin levels for the tumours with the most
adverse characteristics when analysing insulin levels according to
local tumour stage, tumour grade, and PSA levels (Table 1). We
suggest the following interpretation of the dissimilarity: In the
study by Lehrer et al., the sampling of blood used for
measurements of serum levels of insulin was performed after
therapy for prostate cancer had been completed, which was
radioactive implant only for men with low risk, radioactive
implant plus androgen deprivation therapy (ADT) three months
before radiation for men with intermediate risk, and radioactive
implant, external beam therapy, plus (ADT) for men with high
risk. Therefore, it cannot be ruled out that the different forms of
therapy given to each risk group (outcome) may have influenced
the measurement of insulin (exposure). For two of the three groups
therapy included ADT. There are some data in the literature on the
effects of ADT and androgen substitution on insulin levels and
insulin sensitivity in men. In several cross-sectional studies, serum
levels of androgens have been inversely related to insulin levels
and insulin sensitivity (Haffner et al, 1994; Thomas et al, 2000;
Jansson et al, 2002). Furthermore, a recent study showed an
increase in serum levels of insulin and leptin in men who
underwent ADT (Nowicki et al, 2001), whereas in a small clinical
case series, diabetes control deteriorated after ADT (Fukui et al,
2000). On the other hand, several studies have shown improvement
in insulin sensitivity after implementation of androgen supple-
mentation in physiological doses (Marin et al, 1992; Rizza, 2000).
Thus, available data seem to consistently point to an inverse
relationship between serum levels of androgens and insulin. Given
this relationship, we propose that the increased insulin levels in the
high risk group in the study by Lehrer et al. may, at least partially
be due to the low levels of androgens in these men caused by ADT.
Thus, the causality between exposure and outcome may in fact
have been reversed in that study, i.e. the risk group (outcome)
determined the therapy that in turn may have influenced the
serum level of insulin (exposure).
However, the hypothesis that insulin may stimulate prostate
cancer development and growth remains of interest, and a recent
well-designed case control study in China reported a statistically
significant increase in risk of prostate cancer for men with high
levels of insulin (Hsing et al, 2001). Clearly, there is a need for
further well-designed studies addressing this issue.
Table 1
Local tumour stage
a Tumour grade
b PSA level (ng/ml)
c
T1a-c T2 T3, T4 Pdiff 1 2 3 Pdiff o10 10–15 415 Pdiff
Plinearity Plinearity Plinearity
N (%) 63 (43%) 66 (45%) 19 (14%) 76 (51%) 52 (35%) 19 (13%) 63 (43%) 29 (20%) 55 (37%)
Insulin (SD) (mUnits/mL ) 5.7 (13) 6.2 (7.8) 7.2 (16) 0.77 5.4 (12.3) 6.6 (12.0) 7.3 (4.4) 0.77 5.2 (4.9) 7.6 (22.6) 6.6 (6.2) 0.05
0.50 0.52 0.33
Geometric mean of serum insulin levels and (standard deviation) in blood samples from 149 men obtained median time 3.9 years before the diagnosis with prostate cancer in a
previous study (Stattin et al, 2000).
aLocal tumour stage according to the 1992 classification of the Union International contre le cancer (UICC).
bTumour grade according to the
classification of the World Health organization (WHO).
cSerum levels of prostate specific antigen (PSA) at the time of diagnosis. Missing data for one man for tumour stage and
for two men for PSA and tumour grade.
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Sir,
Stattin and Kaaks’s data show that insulin levels increase with
tumour stage, which is what we reported. They do not have a large
enough sample size (sufficient statistical power) to conclude that
there is no difference in the insulin levels of the groups in the table.
I suggest that Stattin and Kaaks collect a larger sample after
determining the sample size; they need to provide 90% power of
detecting a significant (P¼0.05 two-tailed) result. Also, they might
want to measure fasting insulin before breakfast to reduce the
variability of the data, since insulin levels fluctuate throughout the
day and after meals. In the meantime, I refer Stattin, Kaaks and all
interested readers to the article by Altman and Bland (1995), which
eloquently explains the pitfalls of concluding clinical insignificance
when differences between sets of small sample size are found to be
statistically nonsignificant.
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